Astrazeneca Stock News

AstraZeneca forecasts a high teens percentage increase in total revenue in 2022

Astrazeneca said global interest in government purchase agreements for its COVID-19 vaccine was driven by strong demand in Latin America, the Middle East and Asia, even as aggregate global demand this

AstraZeneca PLC (LSE:AZN) said five new drugs had taken on blockbuster status last year generating over US$1bn in revenues each as delivered a strong financial performance, boosted by the US$39bn take

NSW, Victoria and Tasmania reported a total of 41 deaths on Thursday as the Therapeutic Goods Administration provisionally approves the AstraZeneca booster vaccine for adults.

The only surviving key suspect in the 2015 Paris attacks that killed 130 people testified Wednesday that he didnt hurt anyone, even as he proclaimed support for the Islamic State Read more » The post Main Suspect in Paris Attacks Says I Didnt Kill Anyone appeared first on Hamodia . In related news: New Bird Flu Strain Causes Fifth Death in China Iran, Big Power Nuclear Talks Hit Snag on Centrifuge Research Ninth Person Arrested in Belgium Over Paris Attacks S. Korea to Relax Social Distancing Rules Further, Starting May 6 EU Takes on AstraZeneca in Court Over Vaccine Deliveries

NSW and Victoria reported a total of 40 deaths on Thursday as the Therapeutic Goods Administration provisionally approves the AstraZeneca booster vaccine for adults.

Australians have a new option for a Covid-19 booster shot, but there is a catch.

Ross Wightman was diagnosed with Guillain-Barré Syndrome after he was vaccinated with AstraZeneca last year. He spent two months in hospital and has been unable to work since — or get a vaccine exemption — as he tries to access slow-moving government support.

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

AstraZeneca (NASDAQ:AZN) is scheduled to announce Q4 earnings results on Thursday, February 10th, before market open.The consensus EPS Estimate is $0.99 (-7.5% Y/Y) and the

Australia''s medical regulator gives its first green light to the AstraZeneca booster shot for people above the age of 18.

The AstraZeneca vaccine has been provisionally approved as a booster shot against Covid-19 but it has come with some recommendations.

What now for AstraZeneca?  Coming the day after GSK, its former larger rival, AstraZeneca PLC reports following the closure of its Alexion acquisition halfway through last year.

If you are invested in AstraZeneca PLC (LSE:AZN), please look away now. For, the latest results statement from Pfizer has revealed its Covid jab and sales of a new antiviral will generate US$54bn in r

Professor Sir John Bell thinks ''bad behaviour'' from scientists and politicians ''has probably killed hundreds of thousands of people''